Danish pharmaceutical group Lundbeck has acquired the UK and Ireland rights for alcoholism drug nalmefene from Britannia Pharmaceuticals, a unit of Germany's STADA Arzneimittel AG
The drug was developed by Finnish biotechnology company BioTie Therapies Corp, which has been selling the rights to it country by country.
Lundbeck now owns worldwide rights to the drug excluding North America, Mexico, Turkey and South Korea. It plans to conduct additional Phase III studies with nalmefene this year before applying for marketing authorisation in the European Union.
The drug was developed by Finnish biotechnology company BioTie Therapies Corp, which has been selling the rights to it country by country.
Lundbeck now owns worldwide rights to the drug excluding North America, Mexico, Turkey and South Korea. It plans to conduct additional Phase III studies with nalmefene this year before applying for marketing authorisation in the European Union.
No comments:
Post a Comment